期刊文献+

青海红十字医院高危心房颤动患者华法林使用现状调查 被引量:1

原文传递
导出
摘要 目的:调查青海红十字医院高危心房颤动患者华法林使用情况。方法:采用调查问卷形式将我院2012年1月—2012年8月高危心房颤动患者的华法林使用现状进行总结。结果:共收集到全院(1~8)月各相关科室高危心房颤动患者调查资料480份。高危心房颤动患者仅32例(6.6%)使用了华法林抗凝,448例(93.4%)患者未应用华法林。448例未应用华法林的高危心房颤动患者中,216例(48.2%)因经治医师未建议应用华法林,134例(29.9%)因患者无法忍受检测凝血功能时的频繁抽血化验,98例(21.9%)患者因胃肠道出血等副作用而拒绝使用。结论:高危心房颤动患者极易并发脑卒中应及早应用华法林。
出处 《青海医药杂志》 2013年第8期63-64,共2页 Qinghai Medical Journal
  • 相关文献

参考文献2

  • 1何清华.房颤患者华法林治疗临床探讨[J].中国现代药物应用,2010,4(11):32-33. 被引量:6
  • 2卫生部医政司.心房颤动的流行病学和治疗策略.卫生部心血管疾病介入诊疗技术培训教材(心律失常分册).北京:人民卫生出版社,2009,15.

二级参考文献5

共引文献5

同被引文献19

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1402
  • 2黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量:269
  • 3Melgaard L,Gorst-Rasmussen A,Lane DA,et al.Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke,Thromboembo- lism,and Death in Patients With Heart Failure With and Without Atri- al Fibrillation[J].JAM A,2015,314(10):1030-1038.
  • 4Lip GY,Laroche C,Popescu MI,et al.Improved outcomes with Euro- pean Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation:a report from the EORP-AF General Pilot Registry[J].Europace,2015,DOI:http://dx.doi.org/10.1093/europace/ euv269.
  • 5Taylor J,CardioPulse.A focused update to the ESC guidelines for the management of patients with atrial fibrillation[J].Eur Heart J,2012,33(21):2623-2624.
  • 6Rose AJ,Delate T,Ozonoff A,et al.Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Pre- dict Clinically Relevant Bleeding[J J.Circ Cardiovasc QuaI Out- comes,2015,10(8):524-531.
  • 7Pastori D,Pignatelli P,Saiiola M,et al.Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation[J].Int J Cardiol,2015,201:513-516.
  • 8Miyares MA.One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation:Placing Real-World Results Into Perspective[J].JAMA Intern Med,2015,175(7):1242-1243.
  • 9Maura G,Blotiere PO,Bouillon K,et al.Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaxoxa- ban Versus Vitamin K Antagonists:A French Nationwide Propensity- Matched Cohort Study[J].Circulation,2015132(13):1252-1260.
  • 10Prystowsky EN,Padanilam BJ,Fogel RL Treatment of Atrial Fibrilla- tion[J].JAMA,2015,314(3):278-288.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部